Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand.
Southeast Asian J Trop Med Public Health
; 2008 Jan; 39(1): 1-8
Article
em En
| IMSEAR
| ID: sea-33676
To determine the efficacy, safety and tolerability of an alternative short-course, artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum malaria, we compared Artequick--a fixed-dosed combination of artemisinin (80 mg), piperaquine (400 mg), and primaquine (4 mg), per tablet--with a standard regimen of artesunate-mefloquine. A total of 130 patients were randomly assigned to treatment with an orally administered, once-daily, 3-day regimen of either Artequick (Group A: 3.2 mg/Kg/day of artemisinin, 16 mg/Kg/day of piperaquine, and 0.16 mg/Kg/day of primaquine) or artesunate-mefloquine (Group B: artesunate, 4 mg/Kg/day, with mefloquine, 8 mg/Kg/day). Patients receiving each regimen had a rapid clinical and parasitological response. All treatments were well tolerated, and no serious adverse effects occurred. No significant differences were found in fever- and parasite-clearance times between the two study groups. The 28-day cure rates were similarly high, at 98.5% and 100%, in groups A and B, respectively. We conclude that Artequick was as effective and well tolerated as artesunate-mefloquine and could be used as an alternative treatment for multidrug-resistant Plasmodium falciparum malaria in Southeast Asia.
Texto completo:
1
Índice:
IMSEAR
Assunto principal:
Primaquina
/
Quinolinas
/
Tailândia
/
Feminino
/
Humanos
/
Masculino
/
Mefloquina
/
Doença Aguda
/
Estudos Prospectivos
/
Adolescente
Tipo de estudo:
Clinical_trials
/
Observational_studies
País/Região como assunto:
Asia
Idioma:
En
Revista:
Southeast Asian J Trop Med Public Health
Ano de publicação:
2008
Tipo de documento:
Article